Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jul 28, 2013; 19(28): 4552-4558
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4552
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4552
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments
Sheng-Li He, Jie Shen, Xian-Jun Sun, Xiao-Juan Zhu, Department of Hepato-Biliary and Pancreatic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200240, China
Lu-Ming Liu, Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Jing-Cheng Dong, Department of Integrative Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China
Author contributions: Sun XJ, Zhu XJ, Liu LM and Dong JC performed the majority of the study, collected data and followed up the patients; Shen J provided analytical tools and revised the manuscript; He SL designed the study and wrote the manuscript.
Supported by Shanghai Municipal Health Bureau Outstanding Young Clinical Personal Training Project, No. ZYSNXD-YL-YSZK025
Correspondence to: Dr. Sheng-Li He, Department of Hepato-Biliary and Pancreatic Oncology, Fudan University Shanghai Cancer Center, Minhang Branch, Shanghai 200240, China. hlshli@yeah.net
Telephone: +86-21-64629290 Fax: +86-21-64633901
Received: March 21, 2013
Revised: April 25, 2013
Accepted: June 1, 2013
Published online: July 28, 2013
Revised: April 25, 2013
Accepted: June 1, 2013
Published online: July 28, 2013
Core Tip
Core tip: Distant metastases are still obstacles in improvement of outcome in hepatocellular carcinoma (HCC) patients after local treatment. Although, sorafenib is used as a standard systemic treatment for those patients, it is not suitable for patients with intermediate HCC who were not eligible to or failed in the locoregional therapy. This study reports the capecitabine and oxaliplatin regimen for extrahepatic metastasis after local treatment of HCC. The objective response rate was 21.9%, and 40.6% of patients had stable disease, and the median overall survival and the time to tumor progression were 4.2 and 9.2 mo, respectively. Furthermore, the result of this study showed that toxicity profile was tolerated well.